Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (1): 6-13.DOI: 10.19852/j.cnki.jtcm.2023.01.004
• Meta-analysises • Previous Articles Next Articles
Effects of the Huangkui capsule (黄葵胶囊) on chronic kidney disease: a systematic review and Meta-analysis
LI Wei1, XIA Ping2, SUN Wei1, ZHAO Jing1, LIU Qiong1, GENG Lianyi1, ZHOU Yao3(
), GAO Kun1()
- 1 Division of Nephrology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China
2 The First Affiliated Hospital of Soochow University, Suzhou 215000, China
3 Laboratory of Clinical and Experimental Pathology, Department of Pathophysiology, Xuzhou Medical University, Xuzhou 221009, China
-
Received:2021-12-12Accepted:2022-03-28Online:2023-02-15Published:2023-01-10 -
Contact:ZHOU Yao,GAO Kun -
About author:Dr. GAO Kun, Division of Nephrology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China. kungao@njucm.edu.cn. Telephone:+86-13584020606
Dr. ZHOU Yao, Laboratory of Clinical and Experimental Pathology, Department of Pathophysiology, Xuzhou Medical University, Xuzhou 221009, China. zhouyao1226@163.com;
-
Supported by:Study on the mechanism of Yishen Qingli Huoxue formula regulating autophagy in kidney injury caused by metabolic disorder(81774245);The Protective Effect of Abelmoschus Manihot via Regulating NLRP3 Inflammasome—Pyroptosis on Renal Tubule Cells(81873259);The Mechanism of Tanshinone IIA Regulates Txnip/TRX-NLRP3 Inflammasome to Inhibit Pyroptosis and Protect Glomerular Endothelial Cells(82004107);Jiangsu Province Hospital of Chinese Medicine Hospital-level Project，Molecular Mechanism of Abelmoschus Manihot Regulating Fatty Acid Oxidation in Renal Tubule Cells and Antagonizing Renal Fibrosis(Y20026)
Cite this article
LI Wei, XIA Ping, SUN Wei, ZHAO Jing, LIU Qiong, GENG Lianyi, ZHOU Yao, GAO Kun. Effects of the Huangkui capsule (黄葵胶囊) on chronic kidney disease: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 6-13.
share this article
Figure 1 A flowchart of the characteristics of eligible articles
Figure 1 A flowchart of the characteristics of eligible articles
Table 1 Characteristics of included article
| Study | Intervention | Number of participants (treatment/control) | Duration (days) | Result reported | ||
|---|---|---|---|---|---|---|
| Treatment | Control | |||||
| Wei JM et al 201813 | HKC 15+bailing capsule 12 capsules/d | WST | 45/44 | 56 | Scr, 24-h proteinuria | |
| Wang F et al 201214 | HKC 15 | WST | 38/36 | 56 | Scr | |
| Wang EM 2012 | HKC 15+reduced glutathione 1.2 g/d | WST | 20/20 | 56 | Scr, BUN, 24-h proteinuria | |
| Wang YX 2020 | HKC 15+reduced glutathione 2.4 g/d | WST | 50/50 | 56 | 24-h proteinuria | |
| Li F 201916 | HKC 15+Haikun capsule 6 capsules/d | Haikun capsule 6 capsules/d | 57/56 | 84 | Scr, BUN, 24-h proteinuria, GFR | |
| Dai YW et al 201117 | HKC 15+Honghua injection 20 mg/d | WST | 30/25 | 84 | Scr, BUN, 24-h proteinuria, GFR | |
| Cao S et al 20165 | HKC 15+TW 60 mg/d | TW 60 mg/d | 40/40 | 84 | Scr, BUN | |
| Jiang CL 201223 | HKC 15 | WST | 16/16 | 56 | BUN | |
| Mao WJ et al 201218 | HKC 15+telmisartan 80 mg/d | WST | 35/35 | 84 | Scr, 24-h proteinuria, ALB | |
| Dai JH 201319 | HKC 15+Ginkgo-damole injection 20 mg/d | WST | 16/16 | 56 | Scr, BUN, 24-h proteinuria | |
| Heng CZ et al 201320 | HKC 15+losartan potassium 50 mg/d | Losartan pota-ssium 50 mg/d | 30/30 | 84 | Scr, 24-h proteinuria, ALB | |
| Zhang B 201321 | HKC 15+alprostadil injection 20 μg/d | WST | 14/14 | 84 | Scr | |
| Zhang ZX 201622 | HKC 9+valsartan 80 mg/d | WST | 45/45 | 56 | Scr, BUN | |
Table 1 Characteristics of included article
| Study | Intervention | Number of participants (treatment/control) | Duration (days) | Result reported | ||
|---|---|---|---|---|---|---|
| Treatment | Control | |||||
| Wei JM et al 201813 | HKC 15+bailing capsule 12 capsules/d | WST | 45/44 | 56 | Scr, 24-h proteinuria | |
| Wang F et al 201214 | HKC 15 | WST | 38/36 | 56 | Scr | |
| Wang EM 2012 | HKC 15+reduced glutathione 1.2 g/d | WST | 20/20 | 56 | Scr, BUN, 24-h proteinuria | |
| Wang YX 2020 | HKC 15+reduced glutathione 2.4 g/d | WST | 50/50 | 56 | 24-h proteinuria | |
| Li F 201916 | HKC 15+Haikun capsule 6 capsules/d | Haikun capsule 6 capsules/d | 57/56 | 84 | Scr, BUN, 24-h proteinuria, GFR | |
| Dai YW et al 201117 | HKC 15+Honghua injection 20 mg/d | WST | 30/25 | 84 | Scr, BUN, 24-h proteinuria, GFR | |
| Cao S et al 20165 | HKC 15+TW 60 mg/d | TW 60 mg/d | 40/40 | 84 | Scr, BUN | |
| Jiang CL 201223 | HKC 15 | WST | 16/16 | 56 | BUN | |
| Mao WJ et al 201218 | HKC 15+telmisartan 80 mg/d | WST | 35/35 | 84 | Scr, 24-h proteinuria, ALB | |
| Dai JH 201319 | HKC 15+Ginkgo-damole injection 20 mg/d | WST | 16/16 | 56 | Scr, BUN, 24-h proteinuria | |
| Heng CZ et al 201320 | HKC 15+losartan potassium 50 mg/d | Losartan pota-ssium 50 mg/d | 30/30 | 84 | Scr, 24-h proteinuria, ALB | |
| Zhang B 201321 | HKC 15+alprostadil injection 20 μg/d | WST | 14/14 | 84 | Scr | |
| Zhang ZX 201622 | HKC 9+valsartan 80 mg/d | WST | 45/45 | 56 | Scr, BUN | |
Figure 2 Risk of bias graph A: risk of bias item among included studies; B: risk of bias item in each included study
Figure 2 Risk of bias graph A: risk of bias item among included studies; B: risk of bias item in each included study
Figure 3 Results of the Meta-analysis of the efficacy of Huangkui capsule versus control group A: forest plot of comparison of Scr; B: forest plot of comparison of BUN; C: forest plot of comparison of 24-h Urine protein; D: forest plot of comparison of Serum Albumin; E: forest plot of comparison of GFR. Scr: serum creatinine; BUN: blood urea nitrogen; GFR: glomerular filtration rate.
Figure 3 Results of the Meta-analysis of the efficacy of Huangkui capsule versus control group A: forest plot of comparison of Scr; B: forest plot of comparison of BUN; C: forest plot of comparison of 24-h Urine protein; D: forest plot of comparison of Serum Albumin; E: forest plot of comparison of GFR. Scr: serum creatinine; BUN: blood urea nitrogen; GFR: glomerular filtration rate.
Figure 4 Funnel plot including studies A: BUN; B: Scr. BUN: blood urea nitrogen; Scr: serum creatinine.
Figure 4 Funnel plot including studies A: BUN; B: Scr. BUN: blood urea nitrogen; Scr: serum creatinine.
Figure S1 Workflow of the present study
Figure S1 Workflow of the present study
| 1 |
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-72.
DOI PMID |
| 2 |
Perco P, Wilflingseder J, Bernthaler A, et al. Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med 2008; 12: 1177-87.
DOI PMID |
| 3 |
Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379: 815-822.
DOI PMID |
| 4 |
Zhang L, Li P, Xing CY, et al. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial. Am J Kidney Dis 2014; 64: 57-65.
DOI PMID |
| 5 | Cao S, Zhang ZF. A randonmized controlled trail of Huangkui capsule combined with tripterygium wilfordii in the treatment of chronic kidney disease. Zhong Guo Zhong Xi Yi Jie He Shen Bing Za Zhi 2016; 17: 1102-3. |
| 6 | Yu JY, Xiong NN, Guo HF. Clinical observation on diabetic nephropathy treated with alcohol of Abelmoschus manihot. Zhong Guo Zhong Xi Yi Jie He Za Zhi 1995; 15: 263-5. |
| 7 |
Lai X, Liang H, Zhao Y, Wang B. Simultaneous determination of seven active flavonols in the flowers of Abelmoschus manihot by HPLC. J Chromatogr SCI 2009; 47: 206-10.
PMID |
| 8 | Li W, He W, Xia P, et al. Total extracts of Abelmoschus manihot L. attenuates adriamycin-induced renal tubule injury via suppression of ROS-ERK1/2-mediated NLRP3 inflammasome activation. Front Pharmacol 2019; 10: 567-81. |
| 9 |
Zhou L, An XF, Teng SC, et al. Pretreatment with the total flavone glycosides of Flos Abelmoschus manihot and hyperoside prevents glomerular podocyte apoptosis in streptozotocin-induced diabetic nephropathy. J Med Food 2012; 15: 461-8.
DOI PMID |
| 10 | Mao ZM, Shen SM, Wan YG, et al. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to alpha-lipoic acid. J Ethnopharmacol 2015; 173: 256-65. |
| 11 | Tu Y, Sun W, Wan YG, et al. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, ameliorates adriamycin-induced renal inflammation and glomerular injury via inhibiting p38MAPK signaling pathway activity in rats. J Ethnopharmacol 2013; 147: 311-20. |
| 12 | Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and Meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. |
| 13 | Wei JM, Chen Y, Li SS, et al. The influence of Bailing capsule combined with Huangkui capsule on thetreatment of nondialysis patients with chronic renal insufficiency. Liaoning Zhong Yi Za Zhi 2018; 45: 1684-86. |
| 14 | Wang F, Fan YP, Yu Y, Wu JH, Zhang YD. The effect of Huangkui capsule on microinflammation state in patients with chronic kidney disease stage 3. Shi Yong Yi Xue Za Zhi 2012; 28: 1709-10. |
| 15 | Wang EM. Clinical observation of Huangkui capsule combined with reduced glutathione in the treatment of chronic kidney disease. Quan Ke Yi Xue Za Zhi 2012; 15: 1411-3. |
| 16 | Li F, Xu QQ, Zhao XY, Xie FH. Clinical study on Huangkui cap-sules combined with Haikunshenxi capsules in treatment of chro-nic kidney disease. Yong Yao Yu Lin Chuang 2019; 34: 1185-8. |
| 17 | Dai YW, Zhang B. A clinical observation of Huangkui capsule combined with Honghua Injection in the treatment of chronic kidmey disease. Zhong Guo Xian Dai Yao Wu Yin Yong 2011; 5: 95-6. |
| 18 | Mao WJ, Wang JS. Clinical observation of Huangkui capsule combine telmisartan capsules for the treatment of chronic kidney disease with proteinuria. Qiqihar Yi Xue Yuan Xue Bao 2012; 33: 2478-9. |
| 19 | Dai JH. Clinical efficacy observation of Huangkui capsules combined with ginko-damole in treatment of chronic kidney disease. Yao Wu Yu Lin Chuang 2013; 20: 73-5. |
| 20 | Heng CZ, Hou YL, Yang B. Observation on the treatment of chronic kidney disease with proteinuria with Huangkui capsule. Shanxi Zhong Yi Xue Yuan Xue Bao 2013; 14: 49-50. |
| 21 | Zhang B. Clinical efficacy observation of Huangkui capsules combied with Alprostadil injection in treatment of chronic kidney disease. Zhong Guo Yi Yao Zhi Nan 2013; 11: 635-6. |
| 22 | Zhang Z. The effect of Valsartan combined with Huangkui capsule in thr treatment of chronic kidney disease. Zhong Guo Yi Yao Zhi Nan 2016; 7: 133-5. |
| 23 | Jiang CL. Clinical efficacy observation of Huangkui Capsules in treatment of early stage chronic kidney disease. Zhong Guo Yao Wu Jing Ji Xue 2014; 9: 93-4. |
| 24 | Wang YX. Efficacy of Huangkui capsule combined with reduced glutathione in the treatment of chronic kidney disease. Yao Wu Yu Lin Chuang 2020; 39: 97-9. |
| 25 | Song GZ LY. Huang Kui capsule-based therapy in the treatment of 20 patients with IgA nephropathy. J New Chin Med 2005; 37: 78-81. |
| 26 | Zhang QD. The effect of Huangkui capsule on serum SOD, MDA, ET, NO, and urinary protein in patients with chronic kidney disease. Chin J Integr Tradit West Nephrol 2010; 11: 544-5. |
| 27 | Han W, Ma Q, Liu Y, et al. Huangkui capsule alleviates renal tubular epithelial-mesenchymal transition in diabetic nephropathy via inhibiting NLRP3 inflammasome activation and TLR4/NF-κB signaling. Phytomedicine 2019; 57: 203-2. |
| 28 | Tang H, Wan YG, Huang RM, Yang MM, Chen JJ. Huangkui cap-sule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, com- pared to alpha-lipoic acid. J Ethnopharmacol 2015; 73: 256-65. |
| 29 |
Liu S, Ye LF, Tao J, Ge C, Huang LJ, Yu JY. Total flavones of Abelmoschus manihot improve diabetic nephropathy by inhibiting the iRhom2/TACE signalling pathway activity in rats. Pharm Biol 2017; 56: 1, 1-11.
DOI PMID |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
